RBC Capital analyst Ben Hendrix maintains Humana (NYSE:HUM) with a Outperform and raises the price target from $385 to $400.

In collaboration with a leading researcher and professor at Harvard University, Humana's first-of-its-kind study found bett...

Members of Humana Inc.’s senior management team are scheduled to meet with investors and analysts at industry conferences and v...

https://news.sanfordhealth.org/news-release/sanford-to-end-contract-with-humana-medicare-advantage/

Evolent Health is exploring a potential sale, drawing interest from private equity firms like TPG and KKR.

JP Morgan analyst Lisa Gill maintains Humana (NYSE:HUM) with a Neutral and raises the price target from $332 to $396.

Humana will pay $90 million to settle a whistleblower lawsuit alleging it overcharged the government by submitting fraudulent M...